The stock of Puma Biotechnology Inc (NYSE:PBYI) is a huge mover today! About 354,876 shares traded hands. Puma Biotechnology Inc (NYSE:PBYI) has risen 21.49% since April 4, 2016 and is uptrending. It has outperformed by 20.40% the S&P500.
The move comes after 6 months positive chart setup for the $1.30 billion company. It was reported on Nov, 4 by Barchart.com. We have $57.54 PT which if reached, will make NYSE:PBYI worth $741.00 million more.
Analysts await Puma Biotechnology Inc (NYSE:PBYI) to report earnings on November, 14. They expect $-2.05 EPS, down 9.63% or $0.18 from last year’s $-1.87 per share. After $-2.05 actual EPS reported by Puma Biotechnology Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
Puma Biotechnology Inc (NYSE:PBYI) Ratings Coverage
Out of 6 analysts covering Puma Biotechnology Inc (NYSE:PBYI), 5 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 83% are positive. Puma Biotechnology Inc has been the topic of 13 analyst reports since August 27, 2015 according to StockzIntelligence Inc. Stifel Nicolaus upgraded the shares of PBYI in a report on Wednesday, September 21 to “Buy” rating. The company was maintained on Tuesday, March 29 by JP Morgan. Credit Suisse maintained the stock with “Outperform” rating in Tuesday, March 29 report. As per Thursday, September 22, the company rating was maintained by Credit Suisse. Citigroup maintained it with “Buy” rating and $88 target price in Tuesday, March 29 report. The stock has “Sector Perform” rating given by RBC Capital Markets on Tuesday, March 29. The stock of Puma Biotechnology Inc (NYSE:PBYI) earned “Buy” rating by Citigroup on Monday, December 14. The firm earned “Neutral” rating on Thursday, September 3 by Citigroup. UBS maintained the stock with “Buy” rating in Monday, April 11 report. The rating was initiated by JP Morgan on Thursday, August 27 with “Overweight”.
According to Zacks Investment Research, “Puma Biotechnology, Inc. is a biopharmaceutical company focused on the acquisition, in-licensing, development and commercialization of novel therapeutics for the treatment of cancer. Its products under development include PB272 (oral neratinib) for the treatment of patients with human epidermal growth factor receptor type 2 (HER2) positive metastatic breast cancer and gastric cancer and PB272 (neratinib intravenous) for the treatment of patients with advanced cancer. Puma Biotechnology, Inc. is headquartered in Los Angeles, California.”
Insitutional Activity: The institutional sentiment increased to 1.21 in Q2 2016. Its up 0.18, from 1.03 in 2016Q1. The ratio improved, as 24 funds sold all Puma Biotechnology Inc shares owned while 24 reduced positions. 18 funds bought stakes while 40 increased positions. They now own 31.26 million shares or 4.53% more from 29.91 million shares in 2016Q1.
American Grp Inc owns 14,214 shares or 0% of their US portfolio. Swiss National Bank has 0% invested in the company for 45,130 shares. Guggenheim Capital Ltd Liability Co owns 11,555 shares or 0% of their US portfolio. Metropolitan Life Ins Communication Ny has 0% invested in the company for 18,371 shares. Manufacturers Life The holds 17,080 shares or 0% of its portfolio. Janus Cap Mngmt Lc holds 2.54M shares or 0.06% of its portfolio. The New York-based Jpmorgan Chase Company has invested 0% in Puma Biotechnology Inc (NYSE:PBYI). Clough Lp has 0.39% invested in the company for 246,600 shares. Thrivent For Lutherans has 0% invested in the company for 20,260 shares. Diam Limited last reported 0.08% of its portfolio in the stock. Fmr Ltd Com has 0.02% invested in the company for 4.87M shares. Legal General Grp Inc Public Limited has 6,142 shares for 0% of their US portfolio. Dai Ichi Life Insur reported 28,571 shares or 0.03% of all its holdings. New York State Common Retirement Fund holds 0% or 57,300 shares in its portfolio. Geode Cap Management Ltd Liability Corp last reported 0% of its portfolio in the stock.
More important recent Puma Biotechnology Inc (NYSE:PBYI) news were published by: Prnewswire.com which released: “Puma Biotechnology, Inc. Shareholder Alert: Schubert Firm Investigates Company …” on October 11, 2016, also Fool.com published article titled: “Why Puma Biotechnology Inc. Sold Lower Today”, Businesswire.com published: “Puma Biotechnology Closes $172 Million Public Offering of Common Stock” on October 25, 2016. More interesting news about Puma Biotechnology Inc (NYSE:PBYI) was released by: Prnewswire.com and their article: “Johnson & Weaver, LLP Initiates Investigations of Puma Biotechnology, Inc …” with publication date: October 10, 2016.
PBYI Company Profile
Puma Biotechnology, Inc., incorporated on September 15, 2010, is a biopharmaceutical firm that focuses on the development and commercialization of products for the treatment of cancer. The Firm focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2, or HER2, positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.